Myasthenia Gravis: Novel Findings and Perspectives on Traditional to Regenerative Therapeutic Interventions
Source : https://www.aginganddisease.org/EN/10.14336/AD.2022.1215
The prevalence of myasthenia gravis (MG), an autoimmune disorder, is increasing among all subsets of the population leading to an elevated economic and social burden. The pathogenesis of MG is...
Conclusion: The MG progression severely impacts the quality of life and increases the burden on the healthcare system as it demands both personal care and a dedicated therapeutic approach. Though immunosuppressant drugs and steroids are currently available treatment alternatives, the development of refractory MG and related adverse events...
Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO - Neurology and Therapy
Source : https://link.springer.com/article/10.1007/s40120-023-00464-x
Introduction Accurate measurement of myasthenia gravis (MG) severity is required for appropriate clinical monitoring of patients with MG and assessment of the benefit of new treatments in clinical trials. Our...
Conclusion: The severity of MG can be reflected in a meaningful continuum underpinned by the MG-specific outcome measures. Only ocular muscle manifestations were shown to reflect a possibly different facet of MG severity. With its modular nature and comprehensive content, the MG Symptoms PRO provides complementary information to the outcome...
Ravulizumab: A Review in Generalised Myasthenia Gravis - Drugs
Source : https://link.springer.com/article/10.1007/s40265-023-01877-6
Ravulizumab (ULTOMIRIS®) is the first long-acting complement C5 inhibitor (administered intravenously every 8 weeks) to be approved in several countries globally, for adults with generalised myasthenia gravis (gMG) who are...
Conclusions/Relevance: Ravulizumab is an efficacious, generally well tolerated and convenient treatment option in adults with AChR Ab+ gMG, expanding the options available for gMG management.ravulizumab is an efficacious, generally well tolerated and convenient treatment option in adults with AChR Ab+ gMG, expanding the options available for...
Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG)
Source : https://bmjopen.bmj.com/content/13/5/e068104
Objectives This study aims to explore the impact of myasthenia gravis (MG) - in terms of treatments, side effects, comorbidities, psychological health and work or study- in the real world...
Conclusions: This analysis of baseline characteristics of the MyRealWorld MG study population indicates that, despite current treatments, patients experience notable burden. Further scheduled analyses will develop a longitudinal picture of MG burden.
Concordance between patient- and physician-reported Myasthenia Gravis Activities of Daily Living (MG-ADL) scores - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37144893/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Discussion: Our results demonstrate that patients and neurologists have a concordant assessment of the patient's MG symptoms when using the MG-ADL scale. This evidence supports patient self-administration of the MG-ADL in clinical practice and research.